“Crowned” Tröger’s Base Analogues
1
2 H), 2.38 (s, 6 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 148.9,
to afford 3c (126 mg, 72%) as a white solid; m.p. 130–131 °C. H
144.7, 128.6, 128.3, 127.1, 126.9, 126.5, 126.4, 125.6, 125.3, 123.7,
NMR (300 MHz, CDCl3): δ = 7.30–7.15 (m, 4 H), 7.08–6.89 (m, 7
H), 5.01 (s, 1 H), 4.71 (d, J = 16.6 Hz, 1 H), 4.40 (d, J = 16.6 Hz,
1 H), 4.21 (d, J = 16.6 Hz, 1 H), 3.74 (d, J = 16.6 Hz, 1 H), 2.81
(s, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 148.9, 146.9, 143.7,
130.5, 130.0, 129.3, 128.5, 127.2, 126.8, 121.1, 119.6, 116.8, 116.7,
123.6, 90.1, 59.4, 51.5, 41.5 ppm. IR (KBr): ν = 2939, 1444 cm–1.
˜
MS (ESI): m/z (%) = 266 (100) [M + H]. HRMS (ESI) calcd. for
C17H20N3 266.1657; found 266.1651.
Synthesis of Arylalkylamino-Crowned Tröger’s Base Analogues Un-
der Typical Vilsmeier–Haack Conditions. General Procedure 2: N-
Methyl-N-phenylformamide (3 mmol) was cooled in an ice bath
and phosphorus oxychloride (3 mmol) was added dropwise. After
formation of a yellow coloured paste, the reaction mixture was al-
lowed to warm to room temperature. Tröger’s base (1 mmol) dis-
solved in dry dichloromethane (10 mL) was added to the Vilsme-
ier–Haack reagent and the reaction mixture was stirred at room
temperature for 2–4 h. After completion of the reaction (monitor-
ing by TLC), the reaction mixture was poured into saturated
NaHCO3 solution and stirred at room temperature for 1 h. The
aqueous layer was extracted with dichloromethane (3ϫ 10 mL) and
the combined organic extracts were washed with water (3 ϫ
10 mL), dried and concentrated in vacuo. The crude product was
purified by column chromatography with EtOAc/hexane as eluent.
84.4, 59.6, 50.5, 37.8 ppm. IR (KBr): ν = 2923, 1473 cm–1. MS
˜
(ESI): m/z (%) = 486 (100) [M + H]. HRMS (ESI) calcd. for
C22H20N3Br2 484.0023; found 484.0012.
(؎)-N-(2,3,8,9-Tetramethoxy-N,2,8-trimethyl-N-phenyl-6H,12H-
5,11-methanodibenzo[b,f][1,5]diazocin-13-amine (3d): 2,3,8,9-Tetra-
methoxy-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine (1d,
300 mg, 0.87 mmol) in dry CH2Cl2 (8 mL) was added to the
Vilsmeier–Haack reagent prepared from N-methyl-N-phenylfor-
mamide (355 mg, 2.63 mmol) and POCl3 (246 μL, 2.63 mmol). The
crude product was purified by column chromatography with EtOAc
in hexane (10%) as eluent to afford 3d (325 mg, 83%) as a white
1
solid; m.p. 177–178 °C. H NMR (300 MHz, CDCl3): δ = 7.19 (t,
J = 8.2 Hz, 2 H), 7.0 (d, J = 8.2 Hz, 2 H) 6.85 (t, J = 6.8 Hz, 1 H),
6.58 (d, J = 3.6 Hz, 2 H), 6.36 (s, 1 H), 6.29 (s, 1 H), 5.06 (s, 1 H),
4.65 (d, J = 15.5 Hz, 1 H), 4.28 (d, J = 15.5 Hz, 1 H), 4.17 (d, J =
16.4 Hz, 1 H), 3.85 (s, 3 H), 3.83 (s, 3 H), 3.76 (s, 3 H), 3.75 (s, 3
H), 3.70 (d, J = 16.4 Hz, 1 H), 2.83 (s, 3 H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 149.0, 148.4, 146.2, 146.0, 140.8, 137.4,
128.3, 120.0, 119.6, 119.1, 118.2, 108.7, 108.5, 108.4, 108.0, 84.7,
(؎)-N,2,8-Trimethyl-N-phenyl-6H,12H-5,11-methanodibenzo[b,f]-
[1,5]diazocin-13-amine (3a): 2,8-Dimethyl-6H,12H-5,11-methanodi-
benzo[b,f][1,5]diazocine (1a, 250 mg, 1 mmol) in dry CH2Cl2
(8 mL) was added to the Vilsmeier–Haack reagent prepared from
N-methyl-N-phenylformamide (405 mg, 3 mmol) and POCl3
(280 μL, 3 mmol). The crude product was purified by column
chromatography with EtOAc in hexane (5%) as eluent to afford 3a
59.8, 55.8, 55.7, 55.6, 50.2, 36.6 ppm. IR (KBr): ν = 2908,
˜
1503 cm–1. MS (ESI): m/z (%) = 443 (100) [M + H]. HRMS (ESI)
calcd. for C26H30N3O4 448.2236; found 448.2256.
1
(255 mg, 72%) as a pale brown solid; m.p. 135–136 °C. H NMR
(300 MHz, CDCl3): δ = 7.17 (t, J = 7.9 Hz, 2 H), 7.05–6.88 (m, 6
H), 6.84 (t, J = 7.2 Hz, 1 H), 6.69 (s, 1 H), 6.60 (s, 1 H), 5.09 (s, 1
H), 4.70 (d, J = 16.6 Hz, 1 H), 4.34 (d, J = 16.6 Hz, 1 H), 4.22 (d,
J = 15.9 Hz, 1 H), 3.75 (d, J = 16.6 Hz, 1 H), 2.83 (s, 3 H), 2.22
(s, 3 H), 2.20 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 149.0,
145.6, 142.6, 133.3, 133.2, 128.4, 128.1, 128.0, 127.0, 126.8, 125.3,
Crystals were obtained from 200 mg of (Ϯ)-3d in dilute EtOAc
(40 mL) at room temp. after 72 h. A well shaped crystal was picked
for XRD studies.
(؎)-2,8-Dimethyl-13-(piperidin-1-yl)-6H,12H-5,11-methanodi-
benzo[b,f][1,5]diazocine (4): Piperidine-1-carbaldehyde (135 mg,
1.2 mmol) was cooled in an ice bath and phosphorus oxychloride
(112 μL, 1.2 mmol) was added dropwise. The reaction mixture was
then heated to 70 °C and stirred for 1 h to give a yellow coloured
paste. It was then allowed to cool to room temperature, 2,8-di-
methyl-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine (1a,
100 mg, 0.4 mmol) in dry CH2Cl2 (5 mL) was added, and the mix-
ture was stirred at room temperature for 3 h. After completion of
124.8, 119.8, 118.1, 84.6, 60.5, 50.7, 36.5, 20.8 ppm. IR (KBr): ν =
˜
2915, 1494 cm–1. MS (ESI): m/z (%) = 356 (100) [M + H]. HRMS
(ESI) calcd. for C24H26N3 356.2126; found 356.2122.
(؎)-2,8-Dimethoxy-N,2,8-trimethyl-N-(p-tolyl)-6H,12H-5,11-
methanodibenzo[b,f][1,5]diazocin-13-amine (3b): 2,8-Dimethoxy-
6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine (1b, 120 mg,
0.42 mmol) in CH2Cl2 (4 mL) was added to the Vilsmeier–Haack the reaction (monitoring by TLC), the reaction mixture was poured
reagent prepared from N-methyl-N-p-tolylformamide (0.190 mg,
1.27 mmol) and POCl3 (119 μL, 1.27 mmol). The crude product
was purified by column chromatography with EtOAc in hexane
into saturated NaHCO3 solution and stirred at room temp. for 1 h.
The aqueous layer was extracted with dichloromethane (3 ϫ
10 mL) and the combined organic extracts were washed with water
(3ϫ 10 mL), dried and concentrated in vacuo. The crude product
(10%) as eluent to afford 3b (115 mg, 68%) as a pale yellow gummy
1
compound. H NMR (300 MHz, CDCl3): δ = 7.01–6.87 (m, 6 H), was purified by column chromatography with EtOAc in hexane
6.67 (dt, J = 8.7, 2.6 Hz, 2 H), 6.39 (d, J = 2.6 Hz, 1 H), 6.32 (d,
J = 2.8 Hz, 1 H), 4.96 (s, 1 H), 4.67 (d, J = 16.4 Hz, 1 H), 4.36 (d,
J = 16.6 Hz, 1 H), 4.15 (d, J = 16.8 Hz, 1 H), 3.72–3.64 (m, 7 H)
(5%) as eluent to afford 4 (108 mg, 81%) as a pale yellow gummy
compound. H NMR (300 MHz, CDCl3): δ = 6.87–6.73 (m, 4 H),
1
6.53 (d, J = 16.0 Hz, 2 H), 4.44 (d, J = 16.2 Hz, 2 H), 4.01 (d, J =
2.79 (s, 3 H), 2.28 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 16.4 Hz, 1 H), 3.83 (s, 1 H), 3.64 (d, J = 16.0 Hz, 1 H), 2.10 (s, 3
156.0, 155.8, 147.1, 141.2, 137.9, 130.1, 129.5, 129.0, 126.5, 126.1,
119.7, 113.9, 113.8, 110.5, 110.4, 85.2, 60.3, 55.3, 55.2, 51.2, 38.0,
H), 2.01 (s, 3 H), 1.43–1.17 (m, 10 H) ppm. 13C NMR (75 MHz,
CDCl3): δ = 146.3, 142.2, 132.6, 132.2, 128.5, 127.9, 127.7, 127.4,
126.6, 125.2, 124.7, 119.1, 88.7, 59.6, 51.5, 49.7, 29.6, 25.6, 24.9,
20.6 ppm. IR (neat): ν = 2922, 1496 cm–1. MS (ESI): m/z (%) = 402
˜
(100) [M + H]. HRMS (ESI) calcd. for C25H28N3O2 402.2181;
found 402.2196.
20.8, 20.7 ppm. IR (neat): ν = 2925, 1493 cm–1. MS (ESI): m/z (%)
˜
= 334 (100) [M + H]. HRMS (ESI) calcd. for C22H28N3 334.2283;
found 334.2295.
(؎)-2,8-Dibromo-N,2,8-trimethyl-N-phenyl-6H,12H-5,11-methano-
dibenzo[b,f][1,5]diazocin-13-amine (3c): 2,8-Dibromo-6H,12H-5,11-
methanodibenzo[b,f][1,5]diazocine (1c, 138 mg, 0.36 mmol) in dry
CH2Cl2 (8 mL) was added to the Vilsmeier–Haack reagent pre-
pared from N-methyl-N-phenylformamide (147 mg, 1.08 mmol)
and POCl3 (101 μL, 1.08 mmol). The crude product was purified
by column chromatography with EtOAc in hexane (5%) as eluent
(؎)-13-(Morpholin-4-yl)-2,8-dimethyl-6H,12H-5,11-methanodi-
benzo[b,f][1,5]diazocine (5): Morpholine-1-carbaldehyde (248 mg,
2.16 mmol) was cooled in an ice bath and phosphorus oxychloride
(202 μL, 2.16 mmol) was added dropwise. The reaction mixture was
then heated to 70 °C and stirred for 1 h to give a yellow coloured
paste. It was cooled to room temperature, 2,8-dimethyl-6H,12H-
Eur. J. Org. Chem. 2012, 312–319
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.eurjoc.org
317